James D Otvos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/328533/publications.pdf Version: 2024-02-01



IAMES D OTVOS

#	Article	IF	CITATIONS
1	ClycA is associated with neuropsychological impairment in men with HIV. Aids, 2022, 36, 156-159.	2.2	0
2	Calorie restriction improves lipid-related emerging cardiometabolic risk factors in healthy adults without obesity: Distinct influences of BMI and sex from CALERIEâ,,¢ a multicentre, phase 2, randomised controlled trial. EClinicalMedicine, 2022, 43, 101261.	7.1	26
3	Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. Journal of Clinical Lipidology, 2022, 16, 617-625.	1.5	15
4	Effects of Amount, Intensity, and Mode of Exercise Training on Insulin Resistance and Type 2 Diabetes Risk in the STRRIDE Randomized Trials. Frontiers in Physiology, 2021, 12, 626142.	2.8	11
5	The association of novel inflammatory marker GlycA and incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis (MESA). PLoS ONE, 2021, 16, e0248644.	2.5	3
6	High-throughput nuclear magnetic resonance measurement of citrate in serum and plasma in the clinical laboratory. Practical Laboratory Medicine, 2021, 25, e00213.	1.3	9
7	Nuclear Magnetic Resonance Derived Biomarkers for Evaluating Cardiometabolic Risk in Youth and Young Adults Across the Spectrum of Glucose Tolerance. Frontiers in Endocrinology, 2021, 12, 665292.	3.5	5
8	The NIH Lipo-COVID Study: A Pilot NMR Investigation of Lipoprotein Subfractions and Other Metabolites in Patients with Severe COVID-19. Biomedicines, 2021, 9, 1090.	3.2	22
9	A new phenotypic classification system for dyslipidemias based on the standard lipid panel. Lipids in Health and Disease, 2021, 20, 170.	3.0	6
10	The extended lipid panel assay: a clinically-deployed high-throughput nuclear magnetic resonance method for the simultaneous measurement of lipids and Apolipoprotein B. Lipids in Health and Disease, 2020, 19, 247.	3.0	27
11	Association of the Novel Inflammatory Marker GlycA and Incident Heart Failure and Its Subtypes of Preserved and Reduced Ejection Fraction. Circulation: Heart Failure, 2020, 13, e007067.	3.9	16
12	A Newly Developed Diabetes Risk Index, Based on Lipoprotein Subfractions and Branched Chain Amino Acids, is Associated with Incident Type 2 Diabetes Mellitus in the PREVEND Cohort. Journal of Clinical Medicine, 2020, 9, 2781.	2.4	21
13	High Plasma Branched-Chain Amino Acids Are Associated with Higher Risk of Post-Transplant Diabetes Mellitus in Renal Transplant Recipients. Journal of Clinical Medicine, 2020, 9, 511.	2.4	6
14	A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia. JAMA Cardiology, 2020, 5, 540.	6.1	259
15	Ketone Bodies Are Mildly Elevated in Subjects with Type 2 Diabetes Mellitus and Are Inversely Associated with Insulin Resistance as Measured by the Lipoprotein Insulin Resistance Index. Journal of Clinical Medicine, 2020, 9, 321.	2.4	40
16	Concentration of Branched-Chain Amino Acids Is a Strong Risk Marker for Incident Hypertension. Hypertension, 2019, 74, 1428-1435.	2.7	46
17	High Betaine, a Trimethylamine N-Oxide Related Metabolite, Is Prospectively Associated with Low Future Risk of Type 2 Diabetes Mellitus in the PREVEND Study. Journal of Clinical Medicine, 2019, 8, 1813.	2.4	27
18	The novel inflammatory marker GlycA and the prevalence and progression of valvular and thoracic aortic calcification: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 2019, 282, 91-99.	0.8	23

JAMES D ΟΤVOS

#	Article	IF	CITATIONS
19	GlycA, a Novel Inflammatory Marker and Its Association With Peripheral Arterial Disease and Carotid Plaque: The Multi-Ethnic Study of Atherosclerosis. Angiology, 2019, 70, 737-746.	1.8	17
20	Lower Plasma Magnesium, Measured by Nuclear Magnetic Resonance Spectroscopy, is Associated with Increased Risk of Developing Type 2 Diabetes Mellitus in Women: Results from a Dutch Prospective Cohort Study. Journal of Clinical Medicine, 2019, 8, 169.	2.4	16
21	GlycA, a novel inflammatory marker, is associated with subclinical coronary disease. Aids, 2019, 33, 547-557.	2.2	27
22	Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. Annals of the Rheumatic Diseases, 2018, 77, 988-995.	0.9	41
23	Relations of ClycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial. Journal of Clinical Lipidology, 2018, 12, 348-355.e2.	1.5	41
24	A novel NMR-based assay to measure circulating concentrations of branched-chain amino acids: Elevation in subjects with type 2 diabetes mellitus and association with carotid intima media thickness. Clinical Biochemistry, 2018, 54, 92-99.	1.9	71
25	GlycA and hsCRP are independent and additive predictors of future cardiovascular events among patients undergoing angiography: The intermountain heart collaborative study. American Heart Journal, 2018, 202, 27-32.	2.7	26
26	Associations of ideal cardiovascular health with GlycA, a novel inflammatory marker: The Multiâ€Ethnic Study of Atherosclerosis. Clinical Cardiology, 2018, 41, 1439-1445.	1.8	23
27	A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver Disease. Hepatology Communications, 2018, 2, 1467-1478.	4.3	9
28	Plasma Branched-Chain Amino Acids and Risk of Incident Type 2 Diabetes: Results from the PREVEND Prospective Cohort Study. Journal of Clinical Medicine, 2018, 7, 513.	2.4	60
29	Comparability of Lipoprotein Particle Number Concentrations Across ES-DMA, NMR, LC-MS/MS, Immunonephelometry, and VAP: In Search of a Candidate Reference Measurement Procedure for apoB and non-HDL-P Standardization. Clinical Chemistry, 2018, 64, 1485-1495.	3.2	31
30	Does a lack of physical activity explain the rheumatoid arthritis lipid profile?. Lipids in Health and Disease, 2017, 16, 39.	3.0	15
31	NMR quantification of trimethylamine- N -oxide in human serum and plasma in the clinical laboratory setting. Clinical Biochemistry, 2017, 50, 947-955.	1.9	34
32	TMAO is Associated with Mortality: Impact of Modestly Impaired Renal Function. Scientific Reports, 2017, 7, 13781.	3.3	96
33	Association Between Smoking and Serum ClycA and Highâ€Sensitivity Câ€Reactive Protein Levels: The Multiâ€Ethnic Study of Atherosclerosis (MESA) and Brazilian Longitudinal Study of Adult Health (ELSAâ€Brasil). Journal of the American Heart Association, 2017, 6, .	3.7	27
34	Effects of hepato-preferential basal insulin peglispro on nuclear magnetic resonance biomarkers lipoprotein insulin resistance index and GlycA in patients with diabetes. Biomarkers in Medicine, 2017, 11, 991-1001.	1.4	3
35	GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk. Journal of Translational Medicine, 2017, 15, 219.	4.4	163
36	GlycA, a marker of acute phase glycoproteins, and the risk of incident type 2 diabetes mellitus: PREVEND study. Clinica Chimica Acta, 2016, 452, 10-17.	1.1	80

JAMES D ΟΤVOS

#	Article	IF	CITATIONS
37	Comparison of the Predictive Value of GlycA and Other Biomarkers of Inflammation for Total Death, Incident Cardiovascular Events, Noncardiovascular and Noncancer Inflammatory-Related Events, and Total Cancer Events. Clinical Chemistry, 2016, 62, 1020-1031.	3.2	100
38	Differences in GlycA and lipoprotein particle parameters may help distinguish acute kawasaki disease from other febrile illnesses in children. BMC Pediatrics, 2016, 16, 151.	1.7	25
39	Inflammatory glycoproteins in cardiometabolic disorders, autoimmune diseases and cancer. Clinica Chimica Acta, 2016, 459, 177-186.	1.1	66
40	GlycA, a novel proinflammatory glycoprotein biomarker, and high-sensitivity C-reactive protein are inversely associated with sodium intake after controlling for adiposity: the Prevention of Renal and Vascular End-Stage Disease study. American Journal of Clinical Nutrition, 2016, 104, 415-422.	4.7	17
41	A novel inflammatory biomarker, GlycA, associates with disease activity in rheumatoid arthritis and cardio-metabolic risk in BMI-matched controls. Arthritis Research and Therapy, 2016, 18, 86.	3.5	39
42	High-density lipoprotein and inflammation in cardiovascular disease. Translational Research, 2016, 173, 7-18.	5.0	35
43	Longitudinal Evaluation of Lipoprotein Variables in Systemic Lupus Erythematosus Reveals Adverse Changes with Disease Activity and Prednisone and More Favorable Profiles with Hydroxychloroquine Therapy. Journal of Rheumatology, 2016, 43, 745-750.	2.0	53
44	Association of N-Linked Glycoprotein Acetyls and Colorectal Cancer Incidence and Mortality. PLoS ONE, 2016, 11, e0165615.	2.5	31
45	A novel protein glycan biomarker and <scp>LCAT</scp> activity in metabolic syndrome. European Journal of Clinical Investigation, 2015, 45, 850-859.	3.4	30
46	Increase in the Inflammatory Marker GlycA over 13 Years in Young Adults Is Associated with Poorer Cognitive Function in Midlife. PLoS ONE, 2015, 10, e0138036.	2.5	21
47	GlycA, a Pro-Inflammatory Glycoprotein Biomarker, and Incident Cardiovascular Disease: Relationship with C-Reactive Protein and Renal Function. PLoS ONE, 2015, 10, e0139057.	2.5	76
48	GlycA: A Composite Nuclear Magnetic Resonance Biomarker of Systemic Inflammation. Clinical Chemistry, 2015, 61, 714-723.	3.2	286
49	GlycA, a biomarker of inflammatory glycoproteins, is more closely related to the leptin/adiponectin ratio than to glucose tolerance status. Clinical Biochemistry, 2015, 48, 811-814.	1.9	42
50	Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis. Arthritis Research and Therapy, 2015, 17, 117.	3.5	59
51	Lipoprotein Insulin Resistance Index: A Lipoprotein Particle–Derived Measure of Insulin Resistance. Metabolic Syndrome and Related Disorders, 2014, 12, 422-429.	1.3	124
52	Abstract 14731: Glyc A, a Novel Marker of Inflammation, Predicts Cardiovascular Events in HIV-Positive Patients: Results of SMART Study. Circulation, 2014, 130, .	1.6	2
53	Lipids and Lipoproteins and Risk of Different Vascular Events in the MRC/BHF Heart Protection Study. Circulation, 2012, 125, 2469-2478.	1.6	185
54	Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. Journal of Clinical Lipidology, 2011, 5, 105-113.	1.5	311

James D Otvos

#	Article	IF	CITATIONS
55	The surprising AIM-HIGH results are not surprising when viewed through a particle lens. Journal of Clinical Lipidology, 2011, 5, 368-370.	1.5	16
56	HDL Measures, Particle Heterogeneity, Proposed Nomenclature, and Relation to Atherosclerotic Cardiovascular Events. Clinical Chemistry, 2011, 57, 392-410.	3.2	417
57	LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis, 2007, 192, 211-217.	0.8	322
58	Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation, 2006, 113, 1556-1563.	1.6	522
59	Lipoprotein Particle Analysis by Nuclear Magnetic Resonance Spectroscopy. Clinics in Laboratory Medicine, 2006, 26, 847-870.	1.4	619
60	Nuclear Magnetic Resonance Lipoprotein Abnormalities in Prediabetic Subjects in the Insulin Resistance Atherosclerosis Study. Circulation, 2005, 111, 3465-3472.	1.6	222